Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.
2.

Cardiovascular disease in patients with rheumatoid arthritis: impact of classic and disease-specific risk factors.

Cavalli G, Favalli EG.

Ann Transl Med. 2018 Nov;6(Suppl 1):S82. doi: 10.21037/atm.2018.10.72. No abstract available.

3.

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.

Biggioggero M, Crotti C, Becciolini A, Favalli EG.

Drug Des Devel Ther. 2018 Dec 19;13:57-70. doi: 10.2147/DDDT.S150580. eCollection 2019. Review.

4.

The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future.

Biggioggero M, Crotti C, Becciolini A, Miserocchi E, Favalli EG.

Biomed Res Int. 2018 Oct 14;2018:9460187. doi: 10.1155/2018/9460187. eCollection 2018. Review.

5.

The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts.

Favalli EG, Becciolini A, Caporali R, Todoerti M, Iannone F, Dinoia L, Sebastiani M, Spinella A, Gremese E, Cianci F, Atzeni F, Bandinelli F, Ferraccioli G, Lapadula G; GISEA Study Group.

Autoimmun Rev. 2018 Dec;17(12):1251-1258. doi: 10.1016/j.autrev.2018.07.002. Epub 2018 Oct 16. Review.

PMID:
30339886
6.

Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus.

Todoerti M, Favalli EG, Iannone F, Olivieri I, Benucci M, Cauli A, Mathieu A, Santo L, Minisola G, Lapadula G, Bucci R, Gremese E, Caporali R.

Rheumatology (Oxford). 2018 Oct 1;57(57 Suppl 7):vii42-vii53. doi: 10.1093/rheumatology/key195. Review.

PMID:
30289539
7.

Sarilumab: patient-reported outcomes in rheumatoid arthritis.

Crotti C, Biggioggero M, Becciolini A, Favalli EG.

Patient Relat Outcome Meas. 2018 Aug 20;9:275-284. doi: 10.2147/PROM.S147286. eCollection 2018. Review.

8.

The Expanded Risk Score in Rheumatoid Arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthrit.

Salaffi F, Carotti M, Di Carlo M, Tardella M, Lato V, Becciolini A, Favalli EG, Giovagnoni A.

Swiss Med Wkly. 2018 Aug 22;148:w14656. doi: smw.2018.14656. eCollection 2018 Aug 13.

9.

Comments on "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study".

Favalli EG, Conti F, Atzeni F, Selmi C, D'Angelo S, Caporali R, Iannone F.

J Am Acad Dermatol. 2018 Dec;79(6):e119-e120. doi: 10.1016/j.jaad.2018.07.052. Epub 2018 Aug 7. No abstract available.

PMID:
30096421
10.

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.

Favalli EG, Becciolini A, Biggioggero M, Bertoldi I, Crotti C, Raimondo MG, Marchesoni A.

Drug Des Devel Ther. 2018 May 24;12:1421-1429. doi: 10.2147/DDDT.S162286. eCollection 2018.

11.

How advances in personalized medicine will change rheumatology.

Selmi C, Kon E, De Santis M, Favalli EG, Cimaz R, Generali E, Sinigaglia L.

Per Med. 2018 Mar;15(2):75-78. doi: 10.2217/pme-2017-0079. Epub 2018 Feb 2. No abstract available.

PMID:
29714121
12.

Challenges and Advances in Targeting Remission in Axial Spondyloarthritis.

Baraliakos X, Berenbaum F, Favalli EG, Olivieri I, Ostendorf B, Poddubnyy D, DE Vlam K.

J Rheumatol. 2018 Feb;45(2):153-157. doi: 10.3899/jrheum.170222. No abstract available.

13.

Sex and Management of Rheumatoid Arthritis.

Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL.

Clin Rev Allergy Immunol. 2018 Jan 26. doi: 10.1007/s12016-018-8672-5. [Epub ahead of print] Review.

PMID:
29372537
14.

Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.

Iannazzo S, Benucci M, Favalli EG.

Clin Exp Rheumatol. 2018 May-Jun;36(3):479-485. Epub 2018 Jan 15.

PMID:
29352843
15.

Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.

Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R, Bazzani C, Atzeni F, Sarzi Puttini PC, Fusaro E, Pellerito R, Caporali R.

Int J Rheum Dis. 2018 Feb;21(2):422-430. doi: 10.1111/1756-185X.13199. Epub 2017 Oct 30.

PMID:
29082659
16.

The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives.

Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R.

Autoimmun Rev. 2017 Dec;16(12):1185-1195. doi: 10.1016/j.autrev.2017.10.002. Epub 2017 Oct 14. Review.

PMID:
29037899
17.

Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.

Iannone F, Ferraccioli G, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F, Gorla R, Bazzani C, Govoni M, Farina I, Gremese E, Carletto A, Giollo A, Galeazzi M, Foti R, Bianchino L, La Grasta L, Lapadula G.

Clin Rheumatol. 2018 Feb;37(2):315-321. doi: 10.1007/s10067-017-3846-8. Epub 2017 Oct 5.

PMID:
28980085
18.

Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs.

Atzeni F, Carletto A, Foti R, Sebastiani M, Panetta V, Salaffi F, Bonitta G, Iannone F, Gremese E, Govoni M, Marchesoni A, Favalli EG, Gorla R, Ramonda R, Sarzi-Puttini P, Ferraccioli G, Lapadula G; GISEA group.

Joint Bone Spine. 2018 Jul;85(4):455-459. doi: 10.1016/j.jbspin.2017.08.003. Epub 2017 Sep 8.

PMID:
28893679
19.

Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.

Monti S, Todoerti M, Codullo V, Favalli EG, Biggioggero M, Becciolini A, Montecucco C, Caporali R.

Mod Rheumatol. 2018 May;28(3):542-549. doi: 10.1080/14397595.2017.1367076. Epub 2017 Sep 7.

PMID:
28880727
20.

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.

Manara M, Caporali R, Favalli EG, Grosso V, Atzeni F, Sarzi Puttini P, Gorla R, Bazzani C, Fusaro E, Pellerito R, Rocchetta PA, Sinigaglia L.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):804-809. Epub 2017 Jul 27.

PMID:
28770712
21.

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.

Becciolini A, Raimondo MG, Crotti C, Agape E, Biggioggero M, Favalli EG.

Drug Des Devel Ther. 2017 Jun 28;11:1969-1978. doi: 10.2147/DDDT.S138515. eCollection 2017. Review.

22.

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management.

Giacomelli R, Afeltra A, Alunno A, Baldini C, Bartoloni-Bocci E, Berardicurti O, Carubbi F, Cauli A, Cervera R, Ciccia F, Cipriani P, Conti F, De Vita S, Di Benedetto P, Doria A, Drosos AA, Favalli EG, Gandolfo S, Gatto M, Grembiale RD, Liakouli V, Lories R, Lubrano E, Lunardi C, Margiotta DPE, Massaro L, Meroni P, Minniti A, Navarini L, Pendolino M, Perosa F, Pers JO, Prete M, Priori R, Puppo F, Quartuccio L, Ruffatti A, Ruscitti P, Russo B, Sarzi-Puttini P, Shoenfeld Y, Somarakis GA, Spinelli FR, Tinazzi E, Triolo G, Ursini F, Valentini G, Valesini G, Vettori S, Vitali C, Tzioufas AG.

Autoimmun Rev. 2017 Sep;16(9):911-924. doi: 10.1016/j.autrev.2017.07.012. Epub 2017 Jul 11. Review.

PMID:
28705780
23.

Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.

Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL.

Clin Rheumatol. 2017 Aug;36(8):1747-1755. doi: 10.1007/s10067-017-3712-8. Epub 2017 Jun 8.

PMID:
28597133
24.

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.

Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG.

Drug Des Devel Ther. 2017 May 24;11:1593-1603. doi: 10.2147/DDDT.S100302. eCollection 2017. Review.

25.

Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries.

Codullo V, Iannone F, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F, Ferraccioli G, Gremese E, Carletto A, Giollo A, Govoni M, Bergossi F, Galeazzi M, Cantarini L, Salaffi F, Di Carlo M, Bazzani C, Pellerito R, Sebastiani M, Ramonda R, Lapadula G, Caporali R.

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):660-665. Epub 2017 May 8.

PMID:
28516879
26.

Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting.

Favalli EG, Becciolini A, Meroni PL.

J Rheumatol. 2017 Feb;44(2):262-263. doi: 10.3899/jrheum.161045. No abstract available.

PMID:
28148760
27.

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date.

Crotti C, Raimondo MG, Becciolini A, Biggioggero M, Favalli EG.

Drug Des Devel Ther. 2017 Jan 13;11:211-223. doi: 10.2147/DDDT.S104233. eCollection 2017. Review.

28.

Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.

Monti S, Klersy C, Gorla R, Sarzi-Puttini P, Atzeni F, Pellerito R, Fusaro E, Paolazzi G, Rocchetta PA, Favalli EG, Marchesoni A, Caporali R.

Clin Rheumatol. 2017 Apr;36(4):753-761. doi: 10.1007/s10067-016-3528-y. Epub 2017 Jan 5.

PMID:
28058538
29.

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy.

Degli Esposti L, Favalli EG, Sangiorgi D, Di Turi R, Farina G, Gambera M, Ravasio R.

Clinicoecon Outcomes Res. 2016 Dec 21;9:9-17. doi: 10.2147/CEOR.S108730. eCollection 2017.

30.

The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting.

Di Carlo M, Becciolini A, Lato V, Crotti C, Favalli EG, Salaffi F.

J Rheumatol. 2017 Mar;44(3):279-285. doi: 10.3899/jrheum.160924. Epub 2016 Dec 1.

PMID:
27909086
31.

Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.

Favalli EG, Selmi C, Becciolini A, Biggioggero M, Ariani A, Santilli D, Fusaro E, Parisi S, Massarotti M, Marchesoni A, Meroni PL.

Arthritis Care Res (Hoboken). 2017 Jun;69(6):867-874. doi: 10.1002/acr.23090.

32.
33.

Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability.

Iannone F, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F, Caporali R, Codullo V, Ferraccioli G, Gremese E, Carletto A, Giollo A, Govoni M, Bergossi F, Galeazzi M, Cantarini L, Salaffi F, Di Carlo M, Bazzani C, Pellerito R, Sebastiani M, Ramonda R, Lapadula G.

Clin Rheumatol. 2016 Nov;35(11):2649-2656. Epub 2016 Jul 14.

PMID:
27418051
34.

Biomarkers in psoriatic arthritis: a systematic literature review.

Generali E, Scirè CA, Favalli EG, Selmi C.

Expert Rev Clin Immunol. 2016 Jun;12(6):651-60. doi: 10.1586/1744666X.2016.1147954. Epub 2016 Feb 24. Review.

35.

Structural integrity versus radiographic progression in rheumatoid arthritis.

Favalli EG, Becciolini A, Biggioggero M.

RMD Open. 2015 Aug 15;1(Suppl 1):e000064. doi: 10.1136/rmdopen-2015-000064. eCollection 2015. Review.

36.

Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.

Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL.

Arthritis Care Res (Hoboken). 2016 Apr;68(4):432-9. doi: 10.1002/acr.22788.

37.

Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.

Favalli EG, Biggioggero M, Marchesoni A, Meroni PL.

Rheumatology (Oxford). 2015 Jul;54(7):1337. doi: 10.1093/rheumatology/kev209. Epub 2015 Jun 5. No abstract available.

PMID:
26047991
38.

Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism.

Ronda N, Greco D, Adorni MP, Zimetti F, Favari E, Hjeltnes G, Mikkelsen K, Borghi MO, Favalli EG, Gatti R, Hollan I, Meroni PL, Bernini F.

Arthritis Rheumatol. 2015 May;67(5):1155-64. doi: 10.1002/art.39039.

39.

Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.

Biggioggero M, Favalli EG.

Drug Dev Res. 2014 Nov;75 Suppl 1:S38-41. doi: 10.1002/ddr.21192.

PMID:
25381973
40.

Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry.

Favalli EG, Becciolini A, Biggioggero M, Marchesoni A, Meroni PL.

Ann Rheum Dis. 2015 Jan;74(1):e5. doi: 10.1136/annrheumdis-2014-206651. Epub 2014 Oct 10. No abstract available.

PMID:
25304319
41.

Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug?

Favalli EG, Biggioggero M, Meroni PL.

Autoimmun Rev. 2014 Nov;13(11):1102-8. doi: 10.1016/j.autrev.2014.08.026. Epub 2014 Aug 26. Review.

PMID:
25172238
42.

Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.

Filippini M, Bazzani C, Atzeni F, Sarzi Puttini P, Marchesoni A, Favalli EG, Caporali R, Cavagna L, Gorla R.

Biomed Res Int. 2014;2014:416892. doi: 10.1155/2014/416892. Epub 2014 Jul 6.

43.

Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies.

Webb T, Lakos G, Swart A, Gürtler I, Favalli EG, Schioppo T, Mahler M.

Clin Chim Acta. 2014 Nov 1;437:161-7. doi: 10.1016/j.cca.2014.07.032. Epub 2014 Jul 30.

PMID:
25086283
44.

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.

Sebastiani M, Anelli MG, Atzeni F, Bazzani C, Farina I, Fedele AL, Favalli EG, Fineschi I, Cino N, Dal Forno I, Gasparini S, Cassarà E, Giardina R, Bruschi E, Addimanda O, Cassone G, Lopriore S, Sarzi-Puttini P, Filippini M, Pignatti F, Gremese E, Biggioggero M, Manganelli S, Amato G, Caimmi C, Salaffi F, Iannone F, Ferri C, Sandri G, Lapadula G, Gorla R, Govoni M, Ferraccioli G, Marchesoni A, Galeazzi M, Foti R, Carletto A, Cantini F, Triolo G, Epis OM, Salvarani C; Italian Study Group on Early Arthritides (GISEA).

Joint Bone Spine. 2014 Dec;81(6):508-12. doi: 10.1016/j.jbspin.2014.06.011. Epub 2014 Jul 28.

PMID:
25082646
45.

Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs.

Favalli EG, Bugatti S, Biggioggero M, Caporali R.

Biomed Res Int. 2014;2014:831603. doi: 10.1155/2014/831603. Epub 2014 Apr 16. Review.

46.

Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.

Favalli EG, Biggioggero M, Marchesoni A, Meroni PL.

Rheumatology (Oxford). 2014 Sep;53(9):1664-8. doi: 10.1093/rheumatology/keu158. Epub 2014 Apr 12. Erratum in: Rheumatology (Oxford). 2015 Jul;54(7):1337.

PMID:
24729445
47.

The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis.

Favalli EG, Pregnolato F, Biggioggero M, Meroni PL.

Semin Arthritis Rheum. 2014 Jun;43(6):730-7. doi: 10.1016/j.semarthrit.2013.11.006. Epub 2013 Nov 13. Review.

PMID:
24332807
48.

Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores.

Atzeni F, Bongiovanni S, Marchesoni A, Filippini M, Caporali R, Gorla R, Cavagna L, Favalli EG, Saccardo F, Sarzi-Puttini P.

Joint Bone Spine. 2014 Jan;81(1):37-40. doi: 10.1016/j.jbspin.2013.04.005. Epub 2013 Jun 2.

PMID:
23731638
49.

Novel mechanisms of action of the biologicals in rheumatic diseases.

Chighizola CB, Favalli EG, Meroni PL.

Clin Rev Allergy Immunol. 2014 Aug;47(1):6-16. doi: 10.1007/s12016-013-8359-x. Review.

PMID:
23345026
50.

The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials.

Favalli EG, Pregnolato F, Biggioggero M, Meroni PL.

Ther Adv Musculoskelet Dis. 2012 Aug;4(4):213-23. doi: 10.1177/1759720X12449082.

Supplemental Content

Loading ...
Support Center